Company: SXTPW
Filing Date: 2025-02-06
Form Type: 8-K
Source: 0001213900-25-010962
Chunk: 1

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 8-K
Item: Item 1.01
Chunk 1
---
 effect to the exercise, as such
percentage ownership is determined in accordance with the terms of the Warrants. However, any holder may increase or decrease such percentage,
provided that any increase will not be effective until the 61st day after such election.

The exercise price of the Warrants is subject
to customary adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications
or similar events affecting the Common Stock and also upon any distributions of assets, including cash, stock or other property to the
stockholders of the Company.

The issuance of the Warrants pursuant to the Securities
Purchase Agreement and the issuance of the Placement Agent Warrants were made pursuant to the exemption from the registration requirements
under the Securities Act of 1933, as amended (the “ Securities Act”), available to the Company under Section 4(a)(2) promulgated
thereunder and Rule 506 of Regulation D promulgated under the Securities Act due to the fact the offering of
the Warrants and the Placement Agent Warrants thereunder did not involve a public offering of securities.

The Securities Purchase
Agreement contained customary representations and warranties. The offering closed on February 6, 2025.

Pursuant to an engagement
letter agreement between and H. C. Wainwright & Co., LLC (the “ Placement Agent”) dated August 30, 2024, as amended on September
3, 2024 and January 24, 2025 (the “ Engagement Agreement”), the Placement Agent acted as the Company’s exclusive placement
agent in connection with the offering.

Pursuant to the terms
of the Engagement Agreement, the Company paid the Placement Agent a cash transaction fee equal to 7.5% of the aggregate gross cash proceeds
in the offering and a management fee equal to 1.0% of the aggregate gross cash proceeds in the offering. In addition, the Company paid
for certain non-accountable expenses in the amount of $15,000 and a clearing fee in the amount of $10,000. The Company also issued to
the Placement Agent (or its designees) warrants (the “ Placement Agent Warrants”) to purchase up to 112,763 shares of Common
Stock. The Placement Agent Warrants have an exercise price equal to $0.8938 per share and are exercisable upon issuance, or February 6,
2025, for twenty-four months from the date of issuance, or February 8, 2027.